Agios Pharmaceuticals | AGIO - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amgen USD 6.48B 307M 2025-09
Arrowhead Research USD 256.47M 228.7M 2025-09
Astellas Pharma JPY 444.26B 12.55B 2026-03
AstraZeneca USD 12.39B 5M 2025-12
Bayer EUR 5.35B 1.02B 2025-09
Biogen USD 1.65B 34.6M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Daiichi Sankyo JPY 439.83B 95.05B 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Exelixis USD 572.18M 7M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Incyte USD 1.17B 217.51M 2026-03
Ionis Pharmaceuticals USD 195M 40M 2025-12
Merck USD 13.42B 431M 2025-09
Moderna USD 226M 583M 2025-12
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Novartis USD 10.25B 570M 2025-12
Novartis USD 10.82B 694M 2025-09
Pfizer USD 3.54B 7.61B 2025-09
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12